All In Biotech

Drug Trial Radar · NCT03068754

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis

Last checked: Nov 20, 2026Latest source record: Oct 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 143 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

143

Actual

Start

Jun 22, 2017

Primary completion

Nov 25, 2019

Study completion Nov 25, 2019

Sponsor

Lead sponsor
MallinckrodtIndustry
Sponsor type
Industry
First posted
Mar 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

About 213 people with ALS will participate in this study. There will be locations in North and South America. During the first part, participants will be randomly assigned to a group (like by flipping a coin). Out of every 3: * 2 will get the study drug * 1 will get a look-alike with no drug in it (placebo) During the second part, everyone will get the study drug. Participation will help doctors find out if Acthar can help or slow down the symptoms of ALS better than placebo.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • ActharDrug

    Repository corticotropin for subcutaneous injection

  • PlaceboDrug

    Matching placebo for subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Period: Scores on a Scale for Telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)Time frame: Baseline, Week 36
  2. Number of Participants Experiencing an Adverse Event During the Treatment PeriodTime frame: by the end of the treatment period (within 36 Weeks)
  3. Number of Participants Experiencing an Adverse Event by the End of the Trial in the OLE PeriodTime frame: by the time of database lock (within 84 weeks)

Locations

69 sites in 7 countries. Site status is shown where the registry gives one.

  • Neuromuscular Research Center

    Phoenix, Arizona

  • Mayo Clinic - Arizona

    Scottsdale, Arizona

  • University of California San Diego

    La Jolla, California

  • Loma Linda University Health System, Department of Neurology

    Loma Linda, California

  • Keck School of Medicine, University of Southern California

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California Irvine Medical Center

    Orange, California

  • California Pacific Medical Center

    San Francisco, California

  • University of California San Francisco

    San Francisco, California

  • Colorado Springs Neurological Associates

    Colorado Springs, Colorado

  • Georgetown University

    Washington D.C., District of Columbia

  • George Washington University

    Washington D.C., District of Columbia

  • University of Florida - McKnight Brain Institute

    Gainesville, Florida

  • University of South Florida

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Augusta University

    Augusta, Georgia

  • Indiana University-Neuroscience Center of Excellence/Goodman Hall

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky

  • John Hopkins Outpatient Center

    Baltimore, Maryland

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • Mercy Health- Saint Mary's

    Grand Rapids, Michigan

  • Neurology Associates

    Lincoln, Nebraska

  • University of Nebraska Medical Center - Physicians Clinical Neurosciences Center

    Omaha, Nebraska

  • Las Vegas Clinic

    Las Vegas, Nevada

  • Jersey Shore University Medical Center

    Neptune City, New Jersey

  • Columbia Presbyterian Hospital

    New York, New York

  • Providence ALS Center

    Portland, Oregon

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Temple University School of Medicine

    Philadelphia, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Wesley Neurology Clinic

    Cordova, Tennessee

  • Austin Neuromuscular Center

    Austin, Texas

  • Texas Neurology, P.A.

    Dallas, Texas

  • The Methodist Hospital

    Houston, Texas

  • University of Vermont Medical Center

    Colchester, Vermont

  • VCU Medical Center

    Richmond, Virginia

  • Swedish Neuroscience Institute

    Seattle, Washington

  • Medical College of Wisconsin/Froedtert Hospital

    Milwaukee, Wisconsin

  • IADIN

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.